Phase II study of interleukin-4 in indolent B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E5Y92)

• Published in: Journal of immunotherapy (1997) Vol. 33; no. 9; p. 1006
• Main Authors: Wiernik, Peter H, Dutcher, Janice P, Yao, Xiapan, Venkatraj, Usha, Falkson, Carla I, Rowe, Jacob M, Cassileth, Peter A
• Format: Journal Article
• Language: English
• Published: United States 01.11.2010
• Subjects: Adult; Aged; Follow-Up Studies; Humans; Interleukin-4 - administration & dosage; Interleukin-4 - adverse effects; Interleukin-6 - blood; Leukemia, Lymphocytic, Chronic, B-Cell - blood; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - immunology; Leukemia, Lymphocytic, Chronic, B-Cell - mortality; Leukemia, Lymphocytic, Chronic, B-Cell - pathology; Lymphoma, Non-Hodgkin - blood; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - immunology; Lymphoma, Non-Hodgkin - mortality; Lymphoma, Non-Hodgkin - pathology; Male; Middle Aged; Recombinant Proteins - administration & dosage; Recombinant Proteins - adverse effects; Survival Analysis; Treatment Failure; Treatment Outcome
• ISSN: 1537-4513
• DOI: 10.1097/cji.0b013e3181f5dfc5

Recombinant interleukin (IL)-4, 5 μg/kg thrice weekly for 3 weeks followed by a 2-week rest period (1 cycle) was administered to 32 eligible previously treated B-cell chronic lymphocytic leukemia (7 patients) or low-grade B-cell lymphoma patients (25 patients). Two cycles were given before response was evaluated. IL-6 serum levels were evaluated before therapy in all patients and at 12 weeks on study in 7 patients. None of the chronic lymphocytic leukemia patients responded. A partial response was observed in 3 lymphoma patients of 1.2, 3.0, and 3.5 months' duration and stable disease (median 1.5 mo) was observed in another 7 lymphoma patients. The median survival from registration on study was 29.7 months with 7 patients alive at the time of analysis for a median follow-up of 72.8 months. Toxicity was generally mild with no grade 4 nonhematologic toxicity observed. Recombinant IL-4 treatment was well tolerated in this study but had minimal antitumor activity.